Tag Archives: Vitae Pharmaceuticals

September, 2016

March, 2016

  • 18 March

    Vitae Pharmaceuticals Psoriasis Drug Succeeds in Phase 2a Trial

    FORT WASHINGTON, Pa., March 16, 2016 (GLOBE NEWSWIRE) — Vitae Pharmaceuticals, Inc.(NASDAQ:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae’s wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment …